Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.

Antimicrobial Agents and Chemotherapy
E ConnorJ D Connor

Abstract

Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic evaluations. The children tolerated the drug well, and treatment was not associated with any clinically significant adverse effects. Peak concentrations in plasma of 2.5 and 3.0 microM were reached at 90 min after single oral doses of 6 and 10 mg/kg, respectively. The mean systemic availability of oral ribavirin was 42.3%. After 60 days of ribavirin administration, mean trough concentrations in plasma of 2.6 and 4.1 microM were obtained. Ribavirin penetrated well into the cerebrospinal fluid, achieving 70% of the concentration in plasma at steady state.

References

Jan 1, 1990·Journal of Acquired Immune Deficiency Syndromes : JAIDS·R S SchulofM B Sztein
Jan 1, 1990·The International Journal of Biochemistry·T Page, J D Connor
Nov 1, 1990·Reviews of Infectious Diseases·J L Patterson, R Fernandez-Larsson
Aug 1, 1990·The Journal of Pediatrics·S ChandwaniR Welliver
Oct 1, 1987·Clinical Pharmacology and Therapeutics·R B RobertsJ D Connor
May 5, 1989·JAMA : the Journal of the American Medical Association·K Krasinski, W Borkowsky
May 1, 1989·The Journal of Infectious Diseases·C G RayT M Grogan
Jul 5, 1986·Lancet·C CrumpackerJ Connor
Aug 1, 1986·Antimicrobial Agents and Chemotherapy·B E Gilbert, V Knight
Apr 1, 1989·The Journal of Infectious Diseases·J W OgleB A Lauer
Dec 1, 1988·American Journal of Diseases of Children·M G SensionR W Ryder
Aug 1, 1988·The Journal of Infectious Diseases·L E MarkowitzG B Scott
May 1, 1987·Clinical Pharmacology and Therapeutics·O L LaskinR B Roberts
Jan 2, 1986·The New England Journal of Medicine·J B McCormickR Belmont-Williams
Apr 1, 1974·Journal of Pharmacokinetics and Biopharmaceutics·H G BoxenbaumR M Elashoff
Oct 31, 1981·Lancet·V KnightR B Couch
Jul 1, 1982·Antimicrobial Agents and Chemotherapy·C N PowersV Knight
Nov 1, 1983·Antimicrobial Agents and Chemotherapy·R K AustinM F Kagnoff

❮ Previous
Next ❯

Citations

Jun 21, 2001·Annals of Neurology·H T ChongS K Lam
Aug 25, 2001·Indian Journal of Pediatrics·B I Asmar, N M Abdel-Haq
Mar 5, 2003·Antiviral Research·Sai-Kit Lam
Jan 6, 1999·Journal of Hepatology·U Spengler, J K Rockstroh
Jul 12, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·August StichKlaus Fleischer
Nov 17, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·William J MullerRoger Giller
Feb 24, 2001·Viral Immunology·I JordanW I Lipkin
May 6, 2011·The Pediatric Infectious Disease Journal·James E McJunkinRichard J Whitley
Apr 17, 2004·Journal of Gastroenterology and Hepatology·Masaaki ShiinaTooru Shimosegawa
Jan 24, 2009·The Journal of Pharmacology and Experimental Therapeutics·Christopher J EndresJashvant D Unadkat
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Chin-Chung LinLi-Tain Yeh
Feb 22, 2001·Antimicrobial Agents and Chemotherapy·M HosoyaH Suzuki
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Chin-Chung LinLi-Tain Yeh
May 13, 2011·Journal of Virology·Héctor MorenoVerónica Martín
Nov 17, 2009·PLoS Pathogens·Celia PeralesEsteban Domingo
Jul 26, 2006·The Tohoku Journal of Experimental Medicine·Ivana JoksićGordana Joksić
May 23, 2006·AJR. American Journal of Roentgenology·Winnie C W ChuAnil T Ahuja
Oct 5, 2001·Expert Opinion on Pharmacotherapy·N J Snell
Oct 14, 2004·Drug and Chemical Toxicology·Soheila DadgostariDomenico Vitarella
Jun 10, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·G P IlyinC Guguen-Guillouzo
Nov 28, 2008·Medical Hypotheses·Andrew D Haddow, Alastair D Haddow
Feb 20, 2004·Journal of Clinical Pharmacology·Chin-Chung LinLi-Tain Yeh
Feb 4, 2006·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Yifei LiuChin-chung Lin
Jun 1, 2005·Pediatric Clinics of North America·David W Kimberlin
Mar 12, 1998·Infectious Disease Clinics of North America·J E McJunkinT F Tsai
Jan 5, 2012·The American Journal of Pathology·Chelsea M RullerRalph Feuer
Feb 19, 2008·The Journal of Infectious Diseases·Zhao-Hong LiShun-Hua Chen
Jan 16, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rashmi KumarGopa Banerjee
Mar 1, 2018·Oncotarget·Joshua CasaosNicolas Skuli
Oct 6, 2020·SN Comprehensive Clinical Medicine·Shweta JakhmolaHem Chandra Jha
Dec 29, 1999·Pediatric Pulmonology·A K ShettyK M Gutierrez
Mar 19, 2019·Intractable & Rare Diseases Research·Sayantan BanerjeeNaveet Wig
Aug 18, 1999·Journal of the Royal Society of Medicine·A OommenS Nichani

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

© 2021 Meta ULC. All rights reserved